INTRODUCTION
TAVI, aortic valve diseaseEndothelial dysfunction, aortic valve stenosis, (SIRS)Transcatheter aortic valve, aortic stenosis, MP
AORTIC STENOSIS, AORTIC VALVE STENOSIS, PATHOGENESIS, INFLAMMATORY RESPONSE
In patients with aortic valve stenosis undergoing valve intervention, the
inflammatory response is a frequent finding, both in the pathogenesis of calcified
aortic valve diseaseEndothelial dysfunction presents in patients with aortic stenosis and after valve
replacement surgery and elevates the number of circulating endothelial
microparticles (EMP), promoting the inflammatory responseMicroparticles (MP) are membrane fragments (100 nm to 1 µm in diameter)
capable of transferring proteins and nucleic acids from one cell to another. In
patients with aortic stenosis undergoing valve replacement, increased circulating
EMP is linked to triggering of systemic inflammatory response syndrome
(SIRS)Transcatheter aortic valve implantation (TAVI) has been associated with lower levels
of pro-inflammatory interleukins (IL) when compared to the surgical valve
replacement, reflecting the less invasive nature of this procedureThus, the implantation of a sutureless prosthesis, which allows for a faster
procedure, could reduce the impact of cardiopulmonary bypass (CPB) and,
consequently, less inflammatory response that should be characterized by a decrease
in circulating EMP. The aims of this study were to compare the levels of EMP between
patients undergoing aortic valve replacement with conventional bioprosthesis
implantation and with Perceval™ S (LivaNova) and to evaluate its impact on
the inflammatory response in the short-term follow-up.